DaVita saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 80 to 84.
IBD's proprietary rating tracks price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks typically have an RS Rating of over 80 as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
DaVita is working on a consolidation with a 179.60 buy point. See if the stock can break out in heavy trading.
DaVita posted 20% earnings growth in its most recent report. Revenue gains came in at 5%.
The company holds the No. 7 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, Pediatrix Medical and BrightSpring Hlth Svcs are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
